Insulet (PODD) 10-Q 30 Apr 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 28, 2015
Document Documentand Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	PODD
Entity Registrant Name	INSULET CORP
Entity Central Index Key	1145197
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		56,750,931

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current Assets
Cash and cash equivalents	$145,608	$151,193
Accounts receivable, net	36,093	39,882
Inventories	20,065	13,099
Prepaid expenses and other current assets	3,661	4,022
Total current assets	205,427	208,196
Property and equipment, net	44,612	37,069
Intangible assets, net	13,155	14,064
Goodwill	37,536	37,536
Other assets	4,986	5,291
Total assets	305,716	302,156
Current Liabilities
Accounts payable	14,246	14,659
Accrued expenses and other current liabilities	25,267	24,703
Deferred revenue	1,867	1,554
Current portion of capital lease obligations	5,996	3,380
Total current liabilities	47,376	44,296
Capital lease obligations	3,965	2,263
Long-term debt, net of discount	170,595	168,994
Other long-term liabilities	3,038	2,774
Total liabilities	224,974	218,327
Commitments and contingencies (Note 11)
Stockholders’ Equity
Preferred stock, $.001 par value: Authorized: 5,000,000 shares at March 31, 2015 and December 31, 2014 Issued and outstanding: zero shares at March 31, 2015 and December 31, 2014	0	0
Common stock, $.001 par value: Authorized: 100,000,000 shares at March 31, 2015 and December 31, 2014. Issued and outstanding: 56,704,347 and 56,299,022 shares at March 31, 2015 and December 31, 2014, respectively	57	56
Additional paid-in capital	670,544	661,798
Accumulated deficit	-589,859	-578,025
Total stockholders’ equity	80,742	83,829
Total liabilities and stockholders’ equity	$305,716	$302,156

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value (in USD per share)	$0.00	$0.00
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in USD per share)	$0.00	$0.00
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	56,704,347	56,299,022
Common stock, outstanding	56,704,347	56,299,022

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating Expenses [Abstract]
Revenue	$61,215,000	$69,161,000
Cost of revenue	28,408,000	36,353,000
Gross profit	32,807,000	32,808,000
Research and development	8,207,000	6,779,000
General and administrative	15,829,000	14,259,000
Sales and marketing	17,401,000	13,656,000
Total operating expenses	41,437,000	34,694,000
Operating loss	-8,630,000	-1,886,000
Interest income	36,000	31,000
Interest expense	-3,193,000	-4,489,000
Other income, net	5,000	265,000
Interest and other expense, net	-3,152,000	-4,193,000
Loss before income taxes	-11,782,000	-6,079,000
Income tax expense	-52,000	-65,000
Net loss	($11,834,000)	($6,144,000)
Net loss per share basic and diluted	($0.21)	($0.11)
Weighted-average number of shares used in calculating net loss per share	56,496,648	55,089,028

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities
Net loss	($11,834,000)	($6,144,000)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	3,433,000	3,070,000
Non-cash interest and other expense	1,883,000	2,528,000
Stock-based compensation expense	5,305,000	4,360,000
Provision for bad debts	328,000	891,000
Changes in operating assets and liabilities:
Accounts receivable	3,461,000	-4,503,000
Inventories	-6,966,000	-985,000
Deferred revenue	313,000	-288,000
Prepaid expenses and other assets	384,000	-904,000
Accounts payable, accrued expenses and other current liabilities	-59,000	917,000
Other long-term liabilities	264,000	41,000
Net cash used in operating activities	-3,488,000	-1,017,000
Cash flows from investing activities
Purchases of property and equipment	-4,346,000	-2,157,000
Net cash used in investing activities	-4,346,000	-2,157,000
Cash flows from financing activities
Principal payments of capital lease obligations	-1,193,000	-618,000
Proceeds from issuance of common stock	4,876,000	3,561,000
Payment of withholding taxes in connection with vesting of restricted stock units	-1,434,000	-3,882,000
Net cash provided by (used in) financing activities	2,249,000	-939,000
Net decrease in cash and cash equivalents	-5,585,000	-4,113,000
Cash and cash equivalents, beginning of period	151,193,000	149,727,000
Cash and cash equivalents, end of period	145,608,000	145,614,000
Non-cash investing and financing activities
Purchases of property and equipment under capital lease	5,721,000	0
3.75% Convertible Notes
Adjustments to reconcile net loss to net cash used in operating activities
Non-cash interest and other expense	$0	$2,800,000

Nature_of_the_Business

Nature of the Business	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	Nature of the Business
	The Company is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the “OmniPod System”), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager (“PDM”). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to 42 inches of tubing. In contrast, the OmniPod System features two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter.
	In June 2011, the Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, “Neighborhood Diabetes”) in order to expand the Company’s full-suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, the Company is able to provide customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and has the ability to process claims as either durable medical equipment or through pharmacy benefits.
	The Company began commercial sale of the OmniPod System in the United States in 2005. The Company sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The OmniPod System is currently available in multiple countries in Europe and in Canada. The Company has been selling its new OmniPod System since 2013. The new OmniPod System is approximately one-third smaller and one-quarter lighter than the original model, while maintaining the same features and operating capabilities.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Basis of Presentation
	The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three month period ended March 31, 2015 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2015, or for any other subsequent interim period.
	The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
	Use of Estimates in Preparation of Financial Statements
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, goodwill, deferred revenue, and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.
	Principles of Consolidation
	The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
	Cash and Cash Equivalents
	For the purpose of the financial statement classification, the Company considers all highly liquid investment instruments with original maturities of 90 days or less, when purchased, to be cash equivalents. Cash equivalents include money market accounts, which are carried at cost which approximates their fair value. Outstanding letters of credit, related to security deposits for lease obligations, totaled $1.2 million as of March 31, 2015 and December 31, 2014.
	Property and Equipment
	Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the respective assets. Leasehold improvements are amortized over their useful life or the life of the lease, whichever is shorter. Assets acquired under capital leases are amortized in accordance with the respective class of owned assets and the amortization is included with depreciation expense. Maintenance and repair costs are expensed as incurred.
	Goodwill
	Goodwill represents the excess of the cost of the acquired Neighborhood Diabetes businesses over the fair value of identifiable net assets acquired. The Company follows the provisions of FASB ASC 350-20, Intangibles - Goodwill and Other (“ASC 350-20”). The Company performs an assessment of its goodwill for impairment on at least an annual basis or whenever events or changes in circumstances indicate there might be impairment.
	The Company continues to operate in one segment, which is considered to be the sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level. To test for impairment, the Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of its sole reporting unit is less than its carrying amount. This qualitative analysis is used as a basis for determining whether it is necessary to perform the two-step goodwill impairment analysis. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the two-step goodwill impairment test will be performed. The first step compares the carrying value of the reporting unit to its fair value using a discounted cash flow analysis. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. No goodwill impairment was recorded in the three months ended March 31, 2015 or 2014.
	Revenue Recognition
	The Company generates nearly all of its revenue from sales of its OmniPod System and other diabetes related products including blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals to customers and third-party distributors who resell the products to patients with diabetes.
	Revenue recognition requires that persuasive evidence of a sales arrangement exists, delivery of goods occurs through transfer of title and risk and rewards of ownership, the selling price is fixed or determinable and collectability is reasonably assured. With respect to these criteria:
	•	The evidence of an arrangement generally consists of a physician order form, a patient information form and, if applicable, third-party insurance approval for sales directly to patients or a purchase order for sales to a third-party distributor.
	•	Transfer of title and risk and rewards of ownership are passed to the patient or third-party distributor upon shipment of the products.
	•	The selling prices for all sales are fixed and agreed with the patient or third-party distributor and, if applicable, the patient’s third-party insurance provider(s) prior to shipment and are based on established list prices or, in the case of certain third-party insurers, contractually agreed upon prices. Provisions for discounts and rebates to customers are established as a reduction to revenue in the same period the related sales are recorded.
	The Company offers a 45-day right of return for its OmniPod System sales to new patients and defers revenue to reflect estimated sales returns in the same period that the related product sales are recorded. Returns are estimated through a comparison of the Company’s historical return data to its related sales. Historical rates of return are adjusted for known or expected changes in the marketplace when appropriate. When doubt exists about reasonable assuredness of collectability from specific customers, the Company defers revenue from sales of products to those customers until payment is received.
	In June 2011, the Company entered into a development agreement with a U.S. based pharmaceutical company (the "Development Agreement”). Under the Development Agreement, the Company was required to perform design, development, regulatory, and other services to support the pharmaceutical company as it worked to obtain regulatory approval to use the Company’s drug delivery technology as a delivery method for its pharmaceutical. Over the term of the Development Agreement, the Company has invoiced amounts based upon meeting certain deliverable milestones. Revenue on the Development Agreement was recognized using a proportional performance methodology based on efforts incurred and total payments under the agreement. The impact of changes in the expected total effort or contract payments was recognized as a change in estimate using the cumulative catch-up method. The pharmaceutical company received regulatory approval and now purchases product from the Company for use with its pharmaceutical under a supply agreement. Product revenue under this arrangement is recognized at the time that all of the revenue recognition criteria are met, typically upon shipment.
	The Company deferred revenue of $1.9 million and $1.6 million as of March 31, 2015 and December 31, 2014, respectively.
	International sales accounted for 7% and 19% of total revenue during the three months ended March 31, 2015 and 2014, respectively.
	Shipping and Handling Costs
	The Company does not typically charge its customers for shipping and handling costs associated with shipping its product to its customers. These shipping and handling costs are included in general and administrative expenses.
	Concentration of Credit Risk
	Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents. The Company maintains the majority of its cash with two financial institutions.
	The Company purchases complete OmniPods from Flextronics International Ltd., its single source supplier. As of March 31, 2015 and December 31, 2014, liabilities from this vendor represented approximately 23% and 24% of the combined balance of accounts payable, accrued expenses and other current liabilities, respectively.
	In the three months ended March 31, 2015 no single customer represented 10% or more of the Company’s revenue. In the three months ended March 31, 2014, two customers represented 15% and 13% of total revenue, respectively.
	Segment Reporting
	Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker, or decision making group, in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company’s current product offering primarily consists of diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The Company’s current product offering is marketed to a single customer type. As the Company sells a single product type, management operates the business as a single entity.
	Recent Accounting Pronouncements Not Yet Adopted
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 requires that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. Under this guidance, a company may make additional estimates regarding performance conditions and the allocation of variable consideration. The guidance is effective in fiscal years beginning after January 1, 2017, with early adoption permitted. The Company is currently evaluating the impact of ASU 2014-09. The Company has not yet selected a transition method nor has it determined the effect of the standard on our consolidated financial position and results of operations.
	In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718), Accounting for Share-Based Payments when the terms of an award provide that a performance target could be achieve after the requisite service period ("ASU 2014-12"). ASU 2014-12 clarifies the period over which compensation cost would be recognized in awards with a performance target that affects vesting and that could be achieved after the requisite service period. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective in fiscal years beginning after January 1, 2016, with early adoption permitted. The Company is currently evaluating the impact of ASU 2014-12.
	In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs ("ASU 2015-03"). ASU 2015-03 amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. The guidance is effective for annual reporting periods beginning after December 15, 2015, and must be applied retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2015-03.
	Other Significant Policies:
	The following table identifies the Company's other significant accounting policies and the note and page where a detailed description of each policy can be found.
	Fair Value Measurements	Note	3	Page
	Accounts Receivable and Allowance for Doubtful Accounts	Note	7	Page
	Inventories	Note	8	Page
	Intangibles and Other Long-Lived Assets	Note	9	Page
	Warranty	Note	10	Page
	Stock-Based Compensation	Note	12	Page
	Income Taxes	Note	13	Page

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	The Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures (“ASC 820”) related to the fair value measurement of certain of its assets and liabilities. ASC 820 defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A single estimate of fair value results from a complex series of judgments about future events and uncertainties and relies heavily on estimates and assumptions. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following approaches:
	•	Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
	•	Cost approach, which is based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.
	•	Income approach, which is based on the present value of the future stream of net cash flows.
	To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, as described in ASC 820, of which the first two are considered observable and the last unobservable:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — observable inputs other than quoted prices in active markets for identical assets or liabilities
	Level 3 — unobservable inputs in which there is little or no market data available, which require the reporting entity to develop its own assumptions
	The assets and liabilities subject to fair value measurement standards at March 31, 2015 and December 31, 2014 are cash equivalents, consisting of money market funds, and long-term debt which are both based on Level 1 inputs.
	Certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other liabilities are carried at cost, which approximates their fair value because of the short-term maturity of these financial instruments.
	The following tables provides a summary of financial assets that are measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall (in thousands):
		Fair Value Measurements
		Total		Level 1		Level 2		Level 3
	31-Mar-15
	Cash Equivalents - Money Market Funds	$	123,155	$	123,155	$	—	$	—
	31-Dec-14
	Cash Equivalents - Money Market Funds	$	123,141	$	123,141	$	—	$	—
	Debt
	The estimated fair value of debt is based on the Level 1 quoted market prices for the same or similar issues and included the impact of the conversion features.
	The carrying amounts and the estimated fair values of financial instruments as of March 31, 2015 and December 31, 2014, are as follows (in thousands):
		31-Mar-15				December 31, 2014
		Carrying		Estimated Fair		Carrying		Estimated Fair
		Value		Value		Value		Value
	2% Convertible Senior Notes	$	170,595	$	202,377	$	168,994	$	237,475
	The Company issued $201.3 million in principal amount of 2% Notes (as defined below) in June 2014. The carrying value of the 2% Notes at March 31, 2015 includes a debt discount of $30.7 million which is being amortized as non-cash interest expense over the term of the 2% Notes. The decrease in the estimated fair values of these liabilities from December 31, 2014 to March 31, 2015 represents the impact of the quoted bond prices at those dates.

Debt

Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt	Debt
	The Company had outstanding convertible debt and related deferred financing costs on its consolidated balance sheet as follows (in thousands):
		As of
		March 31,			31-Dec-14
		2015
	Principal amount of the 2% Convertible Senior Notes	$	201,250		$	201,250
	Unamortized debt discount	(30,655		)	(32,256		)
	Long-term debt, net of discount	$	170,595		$	168,994
	Deferred financing costs	$	4,693		$	4,974
	Interest expense related to the 3.75% Notes (as defined below) and the 2% Notes was included in interest and other expense on the consolidated statements of operations as follows (in thousands):
		Three Months Ended March 31,
		2015			2014
	Contractual coupon interest	$	1,006		$	1,348
	Accretion of debt discount	1,601			2,625
	Amortization of debt issuance costs	282			146
	Total interest and other expense	$	2,889		$	4,119
	3.75% Convertible Senior Notes
	In June 2011, the Company sold $143.8 million in principal amount of 3.75% Convertible Senior Notes due June 15, 2016 (the "3.75% Notes"). The interest rate on the notes was 3.75% per annum, payable semi-annually in arrears in cash on December 15 and June 15 of each year. The 3.75% Notes were convertible into the Company’s common stock at an initial conversion rate of 38.1749 shares of common stock per $1,000 principal amount of the 3.75% Notes, which was equivalent to a conversion price of approximately $26.20 per share.
	In connection with the issuance of the 3.75% Notes, the Company repurchased $70 million in principal amount of its 5.375% Convertible Senior Notes due June 15, 2013 (the "5.375% Notes") for $85.1 million, a 21.5% premium on the principal amount. The investors that held the $70 million in principal amount of repurchased 5.375% Notes purchased $59.5 million in principal amount of the 3.75% Notes and retained approximately $13.5 million in principal amount of the remaining 5.375% Notes. These investors’ combined $73.0 million in principal amount of convertible debt ($13.5 million of 5.375% Notes and $59.5 million of 3.75% Notes) was considered to be a modification of a portion of the 5.375% Notes and was accounted for separately from the issuance of the remainder of the 3.75% Notes.
	The Company recorded a total debt discount of $25.8 million related to the modified debt. This discount consisted of $10.5 million related to the remaining debt discount on the $70 million in principal amount of 5.375% Notes repurchased, $15.1 million related to the premium payment in connection with the repurchase and $0.2 million related to the increase in the value of the conversion feature. The total debt discount was being amortized as non-cash interest expense at the effective rate of 16.5% over the five year term of the modified debt. Additionally, the Company paid transaction fees of approximately $2.0 million related to the modification, which were recorded as interest and other expense at the time of the modification.
	As of December 31, 2013, the 5.375% Notes were repaid in full and no amounts remained on the Company's balance sheet related to these notes.
	Of the $143.8 million in principal amount of 3.75% Notes issued in June 2011, $84.3 million in principal amount was considered to be an issuance of new debt. The Company recorded a debt discount of $26.6 million related to the $84.3 million in principal amount of 3.75% Notes. The debt discount was recorded as additional paid-in capital to reflect the value of its nonconvertible debt borrowing rate of 12.4% per annum and was being amortized as non-cash interest expense over the five year term of the 3.75% Notes. The Company incurred deferred financing costs related to this offering of approximately $2.8 million, of which $0.9 million has been reclassified as an offset to the value of the amount allocated to equity. The remainder was recorded as other assets in the consolidated balance sheet and was being amortized as non-cash interest expense over the five year term of the 3.75% Notes.
	In June 2014, in connection with the issuance of $201.3 million in principal amount of 2% Convertible Senior Notes due June 15, 2019 (the “2% Notes”), the Company repurchased approximately $114.9 million in principal amount of the 3.75% Notes for $160.7 million, a premium of $45.8 million over the principal amount. Investors that held approximately $80.0 million of 3.75% Notes purchased approximately $98.2 million in principal amount of the 2% Notes. The repurchase of the 3.75% Notes was treated as an extinguishment of debt since the fair value of the conversion feature changed by more than 10%. The extinguishment of the 3.75% Notes was accounted for separately from the issuance of the 2% Notes. The $160.7 million paid to extinguish the debt was allocated to debt and equity based on their respective fair values immediately prior to the transaction. The Company allocated $112.4 million of the payment to the debt and $48.3 million to equity.
	The 3.75% Notes were convertible at the option of the holder during the quarter ended June 30, 2014 since the last reported sales price per share of the Company's common stock was equal to or greater than 130% of the conversion price for at least 20 of the 30 trading days ended on March 31, 2014. The 3.75% Notes and any unpaid interest were convertible at the Company’s option for cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock.
	Beginning on June 20, 2014, the Company had the right to redeem the 3.75% Notes, at its option, in whole or in part, if the last reported sale price per share of the Company’s common stock was at least 130% of the conversion price then in effect for at least 20 trading days during a period of 30 consecutive trading days. In June 2014, the Company met the redemption requirements and notified holders of its intent to redeem the outstanding $28.8 million in principal amount of 3.75% Notes in July 2014. Prior to the redemption date, holders of $28.5 million in principal amount of 3.75% Notes exercised their right to convert their outstanding 3.75% Notes. The Company settled this conversion of the 3.75% Notes in July 2014 by providing cash of $28.5 million for the principal amount of the outstanding 3.75% Notes converted and issuing 348,535 shares of common stock for the conversion premium totaling $12.6 million, for a total consideration paid of $41.1 million. The Company settled the redemption of the remaining $0.3 million in principal amount in exchange for a cash payment of $0.3 million representing principal and accrued and unpaid interest. The Company allocated $27.9 million of the total consideration paid to the debt and $13.5 million to equity.
	The Company recorded a loss on extinguishment of debt of $23.2 million in connection with the repurchase and redemption of the 3.75% Notes during the year ended December 31, 2014, representing the excess of the $140.3 million allocated to the debt over its carrying value, net of deferred financing costs.
	Certain features related to a portion of the 3.75% Notes, including the holders’ ability to require the Company to repurchase their notes and the higher interest payments required in an event of default, were considered embedded derivatives and were required to be bifurcated and accounted for at fair value. The Company assessed the value of these embedded derivatives at each balance sheet date and recorded $0.2 million of other income related to the increase in the fair value of the call feature in the three months ended March 31, 2014.
	No cash interest expense was recorded related to the 3.75% Notes in the three months ended March 31, 2015. Cash interest expense related to the outstanding 3.75% Notes was $1.3 million in the three months ended March 31, 2014. No non-cash interest expense was recorded in the three months ended March 31, 2015 related to the 3.75% Notes, compared to $2.8 million in the three months ended March 31, 2014.
	As of December 31, 2014, no amounts remain outstanding related to the 3.75% Notes.
	2% Convertible Senior Notes
	In June 2014, the Company sold $201.3 million in principal amount of the 2% Notes due June 15, 2019. The interest rate on the notes is 2% per annum, payable semi-annually in arrears in cash on December 15 and June 15 of each year. The 2% Notes are convertible into the Company’s common stock at an initial conversion rate of 21.5019 shares of common stock per $1,000 principal amount of the 2% Notes, which is equivalent to a conversion price of approximately $46.51 per share, subject to adjustment under certain circumstances.
	The Company recorded a debt discount of $35.6 million related to the 2% Notes. The debt discount was recorded as additional paid-in capital to reflect the value of the Company’s nonconvertible debt borrowing rate of 6.2% per annum. This debt discount is being amortized as non-cash interest expense over the five year term of the 2% Notes. The Company incurred deferred financing costs related to this offering of approximately $6.7 million, of which $1.2 million has been reclassified as an offset to the value of the amount allocated to equity. The remainder is recorded as other assets in the consolidated balance sheet and is being amortized as non-cash interest expense over the five year term of the 2% Notes.
	The Company determined that the higher interest and tax payments required in certain circumstances are considered embedded derivatives and should be bifurcated and accounted for at fair value. The Company assesses the value of the embedded derivatives at each balance sheet date. The derivatives had de minimis value at the balance sheet date.
	Cash interest expense related to the 2% Notes was $1.0 million in the three month period ended March 31, 2015. Non-cash interest expense related to the 2% Notes was $1.9 million in the three month period ended March 31, 2015.
	As of March 31, 2015, the Company included $170.6 million on its balance sheet in long-term debt related to the 2% Notes.

Capital_Lease_Obligations

Capital Lease Obligations	3 Months Ended
	Mar. 31, 2015
Leases, Capital [Abstract]
Capital Lease Obligations	Capital Lease Obligations
	As of March 31, 2015 and December 31, 2014, the Company has approximately $13.7 million and $8.0 million of manufacturing equipment acquired under capital leases, respectively. The obligations under the capital leases are being repaid in equal monthly installments over 24 to 36 month terms and include principal and interest payments with an effective interest rate of 13% to 17%.
	The assets have been recorded at their fair value of $13.7 million and are included in property and equipment on the Company's balance sheet as of March 31, 2015. The assets acquired under capital leases are being amortized on a straight-line basis over 5 years in accordance with the Company's policy for depreciation of manufacturing equipment. Amortization expense on assets acquired under capital leases is included with depreciation expense. Amortization expense related to these capital leased assets was $0.5 million and $0.3 million in the three months ended March 31, 2015 and 2014, respectively.
	Assets held under capital leases consist of the following (in thousands):
		As of
		March 31, 2015			December 31, 2014
	Manufacturing equipment	$	13,705		$	7,984
	Less: Accumulated amortization	(2,400		)	(1,885		)
	Total	$	11,305		$	6,099
	The aggregate future minimum lease payments related to these capital leases as of March 31, 2015, are as follows (in thousands):
	Years Ending December 31,	Minimum Lease
		Payments
	2015 (remaining)	$	5,285
	2016	5,639
	2017	269
	Total future minimum lease payments	$	11,193
	Interest expense	(1,232		)
	Total capital lease obligations	$	9,961
	The Company recorded $0.3 million of interest expense on the capital leases in both the three months ended March 31, 2015 and 2014.

Net_Loss_Per_Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2015
Disclosure Potential Common Shares Excluded From Computation Of Diluted Net Loss Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, excluding unvested restricted common shares. Diluted net loss per share is computed using the weighted average number of common shares outstanding and, when dilutive, potential common share equivalents from options, restricted stock units and warrants (using the treasury-stock method), and potential common shares from convertible securities (using the if-converted method). Because the Company reported a net loss for the three months ended March 31, 2015 and 2014, all potential common shares have been excluded from the computation of the diluted net loss per share for all periods presented, as the effect would have been anti-dilutive.
	Potential dilutive common share equivalents consist of the following:
		Three Months Ended March 31,
		2015	2014
	3.75% Convertible Senior Notes	—	5,487,642
	2.00% Convertible Senior Notes	4,327,257	—
	Unvested restricted stock units	961,947	1,024,695
	Outstanding options	2,769,259	1,722,082
	Total dilutive common shares	8,058,463	8,234,419

Accounts_Receivable

Accounts Receivable	3 Months Ended
	Mar. 31, 2015
Receivables [Abstract]
Accounts Receivable	Accounts Receivable
	Accounts receivable consist of amounts due from third-party payors, patients, third-party distributors and government agencies. The Company records an allowance for doubtful accounts at the time potential collection risk is identified. The Company estimates its allowance based on historical experience, assessment of specific risk, discussions with individual customers or various assumptions and estimates that are believed to be reasonable under the circumstances. The Company believes the reserve is adequate to mitigate current collection risk.
	Accounts receivable from one customer represented 13% of gross accounts receivable as of March 31, 2015. As of December 31, 2014 accounts receivable from two customers represented approximately 19% and 10% of gross accounts receivable, respectively.
	The components of accounts receivable are as follows (in thousands):
		As of
		March 31,			31-Dec-14
		2015
	Trade receivables	$	41,469		$	45,719
	Allowance for doubtful accounts	(5,376		)	(5,837		)
	Total accounts receivable	$	36,093		$	39,882

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Disclosure Components Of Inventories [Abstract]
Inventories	Inventories
	Inventories are held at the lower of cost or market, determined under the first-in, first-out method. Inventory has been recorded at cost as of March 31, 2015 and December 31, 2014. Work in process is calculated based upon a buildup in the stage of completion using estimated labor inputs for each stage in production. The Company periodically reviews inventories for net realizable value based on quantities on hand and expectations of future use.
	Inventories consist of the following (in thousands):
		As of
		March 31,		31-Dec-14
		2015
	Raw materials	$	1,616	$	853
	Work-in-process	—		254
	Finished goods	18,449		11,992
	Total inventories	$	20,065	$	13,099

Other_Intangible_Assets

Other Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangible Assets	Other Intangible Assets
	The Company’s finite-lived intangible assets are stated at cost less accumulated amortization. The Company assesses its intangible and other long-lived assets for impairment whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company recognizes an impairment loss for intangibles and other finite-lived assets if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Any such impairment loss is measured as the difference between the carrying amount and the fair value of the asset. The estimation of useful lives and expected cash flows requires the Company to make significant judgments regarding future periods that are subject to some factors outside its control. Changes in these estimates can result in significant revisions to the carrying value of these assets and may result in material charges to the results of operations. The Company recorded $32.9 million of other intangible assets as a result of the acquisition of Neighborhood Diabetes. The estimated life of the acquired tradename asset is 15 years. The estimated useful life of the acquired customer relationship asset is 10 years. Intangible assets with determinable estimated lives are amortized over these lives.
	Other intangible assets consist of the following (in thousands):
		As of
		March 31, 2015							31-Dec-14
		Cost		Accumulated Amortization			Net Book Value		Cost		Accumulated Amortization			Net Book Value
	Customer relationships	$	30,100	$	(19,029	)	$	11,071	$	30,100	$	(18,167	)	$	11,933
	Tradename	2,800		(716		)	2,084		2,800		(669		)	2,131
	Total intangible assets	$	32,900	$	(19,745	)	$	13,155	$	32,900	$	(18,836	)	$	14,064
	Amortization expense related to other intangible assets was approximately $0.9 million and $1.1 million for the three months ended March 31, 2015 and 2014, respectively.
	Amortization expense expected for the next five years and thereafter is as follows (in thousands):
		Amortization Expense
	Years Ending December 31,	Customer Relationships		Tradename			Total
	2015 (remaining)	$	2,202	$	140		$	2,342
	2016	2,478		187			2,665
	2017	2,003		187			2,190
	2018	1,619		187			1,806
	2019	1,309		187			1,496
	Thereafter	1,460		1,196			2,656
	Total	$	11,071	$	2,084		$	13,155
	As of March 31, 2015, the weighted average amortization period of the Company’s intangible assets is approximately 7 years.

Product_Warranty_Costs

Product Warranty Costs	3 Months Ended
	Mar. 31, 2015
Disclosure Product Warranty Liability [Abstract]
Product Warranty Costs	Product Warranty Costs
	The Company provides a four-year warranty on its PDMs and may replace any OmniPods that do not function in accordance with product specifications. The Company estimates its warranty at the time the product is shipped based on historical experience and the estimated cost to service the claims. Cost to service the claims reflects the current product cost which has been decreasing over time. As these estimates are based on historical experience, and the Company continues to introduce new products and versions, the Company also considers the anticipated performance of the product over its warranty period in estimating warranty reserves.
	A reconciliation of the changes in the Company’s product warranty liability is as follows (in thousands):
		Three Months Ended March 31,
		2015			2014
	Balance at the beginning of the period	$	2,614		$	3,090
	Warranty expense	467			693
	Warranty claims settled	(420		)	(683		)
	Balance at the end of the period	$	2,661		$	3,100
		As of
		March 31,			December 31,
		2015			2014
	Composition of balance:
	Short-term	$	975		$	981
	Long-term	1,686			1,633
		$	2,661		$	2,614

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Operating Leases
	The Company leases its facilities in Massachusetts, New York, Florida, and Singapore. The Company’s leases are accounted for as operating leases. The leases generally provide for a base rent plus real estate taxes and certain operating expenses related to the leases. In 2013, the Company entered into a new lease agreement for approximately 90,000 square feet of laboratory and office space for its corporate headquarters in Billerica, Massachusetts. The lease term began in August 2014 and expires in October 2022 and contains escalating payments over the life of the lease. In 2013, the Company extended its Singapore lease which now expires in July 2015. In 2014, the Company amended its existing lease for warehouse space in Billerica, Massachusetts. In addition to extending the term, the Company increased the approximate square footage under the lease. The lease now expires in September 2019. Additionally, in 2014, the Company amended its existing lease for office space in New York which now expires in January 2019. The Company's Florida lease expires in December 2015.
	Certain of the Company’s operating lease agreements contain scheduled rent increases. Rent expense is recorded using the straight-line method and deferred rent is included in other liabilities in the accompanying balance sheets. The Company has considered FASB ASC 840-20, Leases in accounting for these lease provisions.
	The aggregate future minimum lease payments related to these leases as of March 31, 2015, are as follows (in thousands):
	Years Ending December 31,	Minimum Lease
		Payments
	2015 (remaining)	$	1,660
	2016	2,196
	2017	2,284
	2018	2,290
	2019	2,181
	Thereafter	6,080
	Total	$	16,691
	Legal Proceedings
	In October 2013, the Company received a letter from the Office of the Massachusetts Attorney General contending that prior to September 2012 Neighborhood Diabetes engaged in improper sales practices by automatically refilling certain prescriptions for MassHealth patients. The Company responded to this letter, stating that Neighborhood Diabetes’ refill practices during the period in question were appropriate and consistent with applicable laws. The Company entered into a Settlement and Release Agreement and paid approximately $1.5 million in connection with the settlement of this matter in the first quarter of 2015.
	The Company is in the process of responding to a letter of preliminary audit results received in April 2015 on behalf of the Centers for Medicare and Medicaid Services and the State of New York alleging overpayment of certain Medicaid claims to Neighborhood Diabetes.  Due to the preliminary nature of this matter, the Company is not able to assess its ultimate outcome, or reasonably estimate a range of possible loss.
	The Company is, from time to time, involved in the normal course of business in various legal proceedings, including intellectual property, contract employment and product liability suits. Although the Company is unable to quantify the exact financial impact of any of these matters, the Company believes that none of these currently pending matters will have an outcome material to its financial condition or business.
	Indemnifications
	In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.
	In accordance with its bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date under such indemnification obligations and the Company has a director and officer insurance policy that enables it to recover a portion of any amounts paid for future claims.
	The Company is subject to an on-going sales and use tax audit by the Massachusetts Department of Revenue related to Neighborhood Diabetes for a period prior to the acquisition. At March 31, 2015, the Company has recorded a liability related to the assessment by the Massachusetts Department of Revenue. The Company continues to appeal the assessment. Under the Merger Agreement with Neighborhood Diabetes, the Company was indemnified by the former stockholders of Neighborhood Diabetes for any liability resulting from or related to any tax attributable to pre-acquisition periods. In August 2014, the Company entered into a Settlement Agreement with the former stockholders of Neighborhood Diabetes related to certain indemnified items. Amounts received by the Company under the Settlement Agreement were recorded as an offset to expenses in 2014.

Equity

Equity	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity	Equity
	The Company accounts for stock-based compensation under the provisions of FASB ASC 718-10, Compensation — Stock Compensation (“ASC 718-10”), which requires all share-based payments to employees, including grants of employee stock options and restricted stock units, to be recognized in the income statement based on their fair values. Share-based payments that contain performance conditions are recognized when such conditions are probable of being achieved.
	The Company uses the Black-Scholes option pricing model to determine the weighted-average fair value of options granted. The Company determines the intrinsic value of restricted stock and restricted stock units based on the closing price of its common stock on the date of grant. The Company recognizes the compensation expense of share-based awards on a straight-line basis for awards with only service conditions and on an accelerated method for awards with performance conditions. Compensation expense is recognized over the vesting period of the awards.
	The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life of the awards is estimated based on the midpoint scenario, which combines historical exercise data with hypothetical exercise data for outstanding options. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield assumption is based on Company history and expectation of paying no dividends. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest. The Company evaluates the assumptions used to value the awards on a quarterly basis and if factors change and different assumptions are utilized, stock-based compensation expense may differ significantly from what has been recorded in the past. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense.
	In July 2014, in connection with the extinguishment of $28.5 million in principal amount of 3.75% Notes, the Company issued 348,535 shares of its common stock to the holders representing the conversion premium.
	The Company grants share-based awards to employees in the form of options to purchase the Company’s common stock, the ability to purchase stock at a discounted price under the employee stock purchase plan and restricted stock units. Stock-based compensation expense related to share-based awards recognized in the three month periods ended March 31, 2015 and 2014 was $5.3 million and $4.4 million, respectively, and was calculated based on awards ultimately expected to vest.
	At March 31, 2015, the Company had $50.2 million of total unrecognized compensation expense related to unvested stock options and restricted stock units.
	Stock Options
	In May 2007, in conjunction with the Company's initial public offering, the Company adopted its 2007 Stock Option and Incentive Plan (the "2007 Plan"). The 2007 Plan was amended and restated in November 2008 and May 2012 to provide for the issuance of additional shares and to amend certain other provisions. As of March 31, 2015, 999,090 shares remain available for future issuance under the 2007 Plan.
	In the three months ended March 31, 2015, the Company awarded 155,500 shares of performance-based incentive stock options. The stock options were granted under the 2007 Plan and vest over a four year period from the grant date with the potential of an accelerated vesting period pursuant to the achievement of certain performance conditions.
	The following summarizes the activity under the Company’s stock option plans:
		Number of		Weighted Average		Aggregate
		Options (#)		Exercise Price ($)		Intrinsic
						Value ($)
						(In thousands)
	Balance, December 31, 2014	1,847,669		$	26.99
	Granted	1,271,391		33.98
	Exercised(1)	(319,079	)	15.35		$	6,958
	Canceled	(30,722	)	28.11
	Balance, March 31, 2015	2,769,259		$	31.53	$	12,063
	Vested, March 31, 2015(2)	830,911		$	25.27	$	8,401
	Vested and expected to vest, March 31, 2015(2)(3)	2,538,150				$	11,696
	(1)	The aggregate intrinsic value was calculated based on the positive difference between the estimated fair value of the Company’s common stock as of the date of exercise and the exercise price of the underlying options.
	(2)	The aggregate intrinsic value was calculated based on the positive difference between the estimated fair value of the Company’s common stock as of March 31, 2015, and the exercise price of the underlying options.
	(3)	Represents the number of vested options as of March 31, 2015, plus the number of unvested options expected to vest as of March 31, 2015, based on the unvested options outstanding at March 31, 2015, adjusted for the estimated forfeiture.
	At March 31, 2015 there were 2,769,259 options outstanding with a weighted average exercise price of $31.53 and a weighted average remaining contractual life of 8.5 years. At March 31, 2015 there were 830,911 options exercisable with a weighted average exercise price of $25.27 and a weighted average remaining contractual life of 6.6 years.
	Employee stock-based compensation expense related to stock options in the three month periods ended March 31, 2015 and 2014 was $3.0 million and $1.6 million, respectively, and was based on awards ultimately expected to vest. At March 31, 2015, the Company had $23.6 million of total unrecognized compensation expense related to stock options that will be recognized over a weighted average period of 1.5 years.
	Employee Stock Purchase Plan
	As of March 31, 2015 and 2014 the Company had no shares contingently issued under the employee stock purchase plan (“ESPP”). In the three months ended March 31, 2015 and 2014, the Company recorded no significant stock-based compensation charges related to the ESPP.
	Restricted Stock Units
	In the three months ended March 31, 2015, the Company awarded 418,584 restricted stock units to certain employees. The restricted stock units were granted under the 2007 Plan and vest annually over a three year period from the grant date. There were no restricted stock units subject to the achievement of performance conditions (performance-based restricted stock units) awarded in the three month period ended March 31, 2015. The restricted stock units granted have a weighted average fair value of $33.81 per share based on the closing price of the Company’s common stock on the date of grant. The restricted stock units granted during the three months ended March 31, 2015 were valued at approximately $14.2 million on their grant date, and the Company is recognizing the compensation expense over the vesting period. Approximately $2.3 million and $2.8 million of stock compensation expense related to the vesting of restricted stock units was recognized in the three months ended March 31, 2015 and 2014, respectively. Approximately $26.6 million of the fair value of the restricted stock units remained unrecognized as of March 31, 2015 and will be recognized over a weighted average period of 1.5 years. Under the terms of the awards, the Company will issue shares of common stock on each of the vesting dates.
	The following table summarizes the status of the Company’s restricted stock units:
		Number of		Weighted
		Shares (#)		Average
				Fair Value ($)
	Balance, December 31, 2014	746,612		$	31.4
	Granted	418,584		33.81
	Vested	(132,476	)	29.68
	Forfeited	(70,773	)	35.72
	Balance, March 31, 2015	961,947		$	32.35

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect in the years in which the differences are expected to reverse. A valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company reviews its deferred tax assets for recoverability considering historical profitability, projected future taxable income, and the expected timing of the reversals of existing temporary differences and tax planning strategies. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
	The Company follows the provisions of FASB ASC 740-10, Income Taxes (“ASC 740-10”) on accounting for uncertainty in income taxes recognized in its financial statements. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In addition, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company recognizes estimated interest and penalties for uncertain tax positions in income tax expense.
	The Company files federal, state and foreign tax returns. These returns are generally open to examination by the relevant tax authorities from three to four years from the date they are filed. The tax filings relating to the Company's federal and state tax returns are currently open to examination for tax years 2011 through 2013 and 2010 through 2013, respectively. In addition, the Company has generated tax losses since its inception in 2000. These years may be subject to examination if the losses are carried forward and utilized in future years.
	At March 31, 2015 and December 31, 2014, the Company provided a valuation allowance for the full amount of its net deferred tax asset because it is not more likely than not that the future tax benefit will be realized.
	Income tax expense consists of the following (in thousands):
		Three Months Ended March 31,
		2015		2014
	Current	$	24	$	31
	Deferred	28		34
	Total	$	52	$	65
	In the three months ended March 31, 2015 and 2014, the current portion of income tax expense primarily related to state and foreign taxes, and the deferred portion primarily related to U.S. Federal and State amounts.
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes as well as federal and state net operating losses and tax credit carryforwards.
	In the future, the Company will generate additional deferred tax assets and liabilities related to its amortization of acquired intangible assets for tax purposes because these long-lived intangible assets are not amortized for financial reporting purposes. The tax amortization in future years will give rise to a temporary difference and a tax liability, which will only reverse at the time of ultimate sale or further impairment of the underlying intangible assets. Due to the uncertain timing of this reversal, the temporary difference cannot be considered as a source of future taxable income for purposes of determining a valuation allowance; therefore, the tax liability cannot be used to offset the deferred tax asset related to the net operating loss carryforward for tax purposes that will be generated by the same amortization.
	The Company had no unrecognized tax benefits at March 31, 2015.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Basis of Presentation	Basis of Presentation
	The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three month period ended March 31, 2015 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2015, or for any other subsequent interim period.
	The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
Use of Estimates in Preparation of Financial Statements	Use of Estimates in Preparation of Financial Statements
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, goodwill, deferred revenue, and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.
Principles of Consolidation	Principles of Consolidation
	The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
Cash and Cash Equivalents	Cash and Cash Equivalents
	For the purpose of the financial statement classification, the Company considers all highly liquid investment instruments with original maturities of 90 days or less, when purchased, to be cash equivalents. Cash equivalents include money market accounts, which are carried at cost which approximates their fair value. Outstanding letters of credit, related to security deposits for lease obligations, totaled $1.2 million as of March 31, 2015 and December 31, 2014.
Property and Equipment	Property and Equipment
	Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the respective assets. Leasehold improvements are amortized over their useful life or the life of the lease, whichever is shorter. Assets acquired under capital leases are amortized in accordance with the respective class of owned assets and the amortization is included with depreciation expense. Maintenance and repair costs are expensed as incurred.
Goodwill	Goodwill
	Goodwill represents the excess of the cost of the acquired Neighborhood Diabetes businesses over the fair value of identifiable net assets acquired. The Company follows the provisions of FASB ASC 350-20, Intangibles - Goodwill and Other (“ASC 350-20”). The Company performs an assessment of its goodwill for impairment on at least an annual basis or whenever events or changes in circumstances indicate there might be impairment.
	The Company continues to operate in one segment, which is considered to be the sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level. To test for impairment, the Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of its sole reporting unit is less than its carrying amount. This qualitative analysis is used as a basis for determining whether it is necessary to perform the two-step goodwill impairment analysis. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the two-step goodwill impairment test will be performed. The first step compares the carrying value of the reporting unit to its fair value using a discounted cash flow analysis. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. No goodwill impairment was recorded in the three months ended March 31, 2015 or 2014.
Revenue Recognition	Revenue Recognition
	The Company generates nearly all of its revenue from sales of its OmniPod System and other diabetes related products including blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals to customers and third-party distributors who resell the products to patients with diabetes.
	Revenue recognition requires that persuasive evidence of a sales arrangement exists, delivery of goods occurs through transfer of title and risk and rewards of ownership, the selling price is fixed or determinable and collectability is reasonably assured. With respect to these criteria:
	•	The evidence of an arrangement generally consists of a physician order form, a patient information form and, if applicable, third-party insurance approval for sales directly to patients or a purchase order for sales to a third-party distributor.
	•	Transfer of title and risk and rewards of ownership are passed to the patient or third-party distributor upon shipment of the products.
	•	The selling prices for all sales are fixed and agreed with the patient or third-party distributor and, if applicable, the patient’s third-party insurance provider(s) prior to shipment and are based on established list prices or, in the case of certain third-party insurers, contractually agreed upon prices. Provisions for discounts and rebates to customers are established as a reduction to revenue in the same period the related sales are recorded.
	The Company offers a 45-day right of return for its OmniPod System sales to new patients and defers revenue to reflect estimated sales returns in the same period that the related product sales are recorded. Returns are estimated through a comparison of the Company’s historical return data to its related sales. Historical rates of return are adjusted for known or expected changes in the marketplace when appropriate. When doubt exists about reasonable assuredness of collectability from specific customers, the Company defers revenue from sales of products to those customers until payment is received.
	In June 2011, the Company entered into a development agreement with a U.S. based pharmaceutical company (the "Development Agreement”). Under the Development Agreement, the Company was required to perform design, development, regulatory, and other services to support the pharmaceutical company as it worked to obtain regulatory approval to use the Company’s drug delivery technology as a delivery method for its pharmaceutical. Over the term of the Development Agreement, the Company has invoiced amounts based upon meeting certain deliverable milestones. Revenue on the Development Agreement was recognized using a proportional performance methodology based on efforts incurred and total payments under the agreement. The impact of changes in the expected total effort or contract payments was recognized as a change in estimate using the cumulative catch-up method. The pharmaceutical company received regulatory approval and now purchases product from the Company for use with its pharmaceutical under a supply agreement. Product revenue under this arrangement is recognized at the time that all of the revenue recognition criteria are met, typically upon shipment.
	The Company deferred revenue of $1.9 million and $1.6 million as of March 31, 2015 and December 31, 2014, respectively.
	International sales accounted for 7% and 19% of total revenue during the three months ended March 31, 2015 and 2014, respectively.
Shipping and Handling Cost	Shipping and Handling Costs
	The Company does not typically charge its customers for shipping and handling costs associated with shipping its product to its customers. These shipping and handling costs are included in general and administrative expenses.
Concentration of Credit Risk	Concentration of Credit Risk
	Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents. The Company maintains the majority of its cash with two financial institutions.
	The Company purchases complete OmniPods from Flextronics International Ltd., its single source supplier. As of March 31, 2015 and December 31, 2014, liabilities from this vendor represented approximately 23% and 24% of the combined balance of accounts payable, accrued expenses and other current liabilities, respectively.
	In the three months ended March 31, 2015 no single customer represented 10% or more of the Company’s revenue. In the three months ended March 31, 2014, two customers represented 15% and 13% of total revenue, respectively.
Segment Reporting	Segment Reporting
	Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker, or decision making group, in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company’s current product offering primarily consists of diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The Company’s current product offering is marketed to a single customer type. As the Company sells a single product type, management operates the business as a single entity.
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 requires that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. Under this guidance, a company may make additional estimates regarding performance conditions and the allocation of variable consideration. The guidance is effective in fiscal years beginning after January 1, 2017, with early adoption permitted. The Company is currently evaluating the impact of ASU 2014-09. The Company has not yet selected a transition method nor has it determined the effect of the standard on our consolidated financial position and results of operations.
	In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718), Accounting for Share-Based Payments when the terms of an award provide that a performance target could be achieve after the requisite service period ("ASU 2014-12"). ASU 2014-12 clarifies the period over which compensation cost would be recognized in awards with a performance target that affects vesting and that could be achieved after the requisite service period. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective in fiscal years beginning after January 1, 2016, with early adoption permitted. The Company is currently evaluating the impact of ASU 2014-12.
	In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs ("ASU 2015-03"). ASU 2015-03 amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. The guidance is effective for annual reporting periods beginning after December 15, 2015, and must be applied retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2015-03.

Fair_Value_Measurements_Fair_V

Fair Value Measurements Fair Value of Financial Instruments (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Fair Value of Financial Instruments	The Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures (“ASC 820”) related to the fair value measurement of certain of its assets and liabilities. ASC 820 defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A single estimate of fair value results from a complex series of judgments about future events and uncertainties and relies heavily on estimates and assumptions. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following approaches:
	•	Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
	•	Cost approach, which is based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.
	•	Income approach, which is based on the present value of the future stream of net cash flows.
	To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, as described in ASC 820, of which the first two are considered observable and the last unobservable:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — observable inputs other than quoted prices in active markets for identical assets or liabilities
	Level 3 — unobservable inputs in which there is little or no market data available, which require the reporting entity to develop its own assumptions

Accounts_Receivable_Trade_and_

Accounts Receivable Trade and Other Accounts Receivable Policy (Policies)	3 Months Ended
	Mar. 31, 2015
Inventory Policy [Abstract]
Accounts Receivable and Allowance for Doubtful Accounts	Accounts receivable consist of amounts due from third-party payors, patients, third-party distributors and government agencies. The Company records an allowance for doubtful accounts at the time potential collection risk is identified. The Company estimates its allowance based on historical experience, assessment of specific risk, discussions with individual customers or various assumptions and estimates that are believed to be reasonable under the circumstances. The Company believes the reserve is adequate to mitigate current collection risk.

Inventories_Inventory_Policy_P

Inventories Inventory Policy (Policies)	3 Months Ended
	Mar. 31, 2015
Inventory Policy [Abstract]
Inventories	Inventories are held at the lower of cost or market, determined under the first-in, first-out method. Inventory has been recorded at cost as of March 31, 2015 and December 31, 2014. Work in process is calculated based upon a buildup in the stage of completion using estimated labor inputs for each stage in production. The Company periodically reviews inventories for net realizable value based on quantities on hand and expectations of future use.

Other_Intangible_Assets_Accoun

Other Intangible Assets Accounting Policies Other Intangible Assets (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Intangibles and Other Long-Lived Assets	The Company’s finite-lived intangible assets are stated at cost less accumulated amortization. The Company assesses its intangible and other long-lived assets for impairment whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company recognizes an impairment loss for intangibles and other finite-lived assets if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Any such impairment loss is measured as the difference between the carrying amount and the fair value of the asset. The estimation of useful lives and expected cash flows requires the Company to make significant judgments regarding future periods that are subject to some factors outside its control. Changes in these estimates can result in significant revisions to the carrying value of these assets and may result in material charges to the results of operations. The Company recorded $32.9 million of other intangible assets as a result of the acquisition of Neighborhood Diabetes. The estimated life of the acquired tradename asset is 15 years. The estimated useful life of the acquired customer relationship asset is 10 years. Intangible assets with determinable estimated lives are amortized over these lives.

Product_Warranty_Costs_Standar

Product Warranty Costs Standard Product Warranty Policy (Policies)	3 Months Ended
	Mar. 31, 2015
Inventory Policy [Abstract]
Warranty	The Company provides a four-year warranty on its PDMs and may replace any OmniPods that do not function in accordance with product specifications. The Company estimates its warranty at the time the product is shipped based on historical experience and the estimated cost to service the claims. Cost to service the claims reflects the current product cost which has been decreasing over time. As these estimates are based on historical experience, and the Company continues to introduce new products and versions, the Company also considers the anticipated performance of the product over its warranty period in estimating warranty reserves.

Equity_Stock_Based_Compensatio

Equity Stock Based Compensation (Policies)	3 Months Ended
	Mar. 31, 2015
Share Based Compensation Policy [Abstract]
Stock-Based Compensation	The Company accounts for stock-based compensation under the provisions of FASB ASC 718-10, Compensation — Stock Compensation (“ASC 718-10”), which requires all share-based payments to employees, including grants of employee stock options and restricted stock units, to be recognized in the income statement based on their fair values. Share-based payments that contain performance conditions are recognized when such conditions are probable of being achieved.
	The Company uses the Black-Scholes option pricing model to determine the weighted-average fair value of options granted. The Company determines the intrinsic value of restricted stock and restricted stock units based on the closing price of its common stock on the date of grant. The Company recognizes the compensation expense of share-based awards on a straight-line basis for awards with only service conditions and on an accelerated method for awards with performance conditions. Compensation expense is recognized over the vesting period of the awards.
	The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life of the awards is estimated based on the midpoint scenario, which combines historical exercise data with hypothetical exercise data for outstanding options. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield assumption is based on Company history and expectation of paying no dividends. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest. The Company evaluates the assumptions used to value the awards on a quarterly basis and if factors change and different assumptions are utilized, stock-based compensation expense may differ significantly from what has been recorded in the past. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense.

Income_Taxes_Income_Tax_Polici

Income Taxes Income Tax (Policies)	3 Months Ended
	Mar. 31, 2015
Income Tax Policy [Abstract]
Income Taxes	The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect in the years in which the differences are expected to reverse. A valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company reviews its deferred tax assets for recoverability considering historical profitability, projected future taxable income, and the expected timing of the reversals of existing temporary differences and tax planning strategies. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
	The Company follows the provisions of FASB ASC 740-10, Income Taxes (“ASC 740-10”) on accounting for uncertainty in income taxes recognized in its financial statements. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In addition, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company recognizes estimated interest and penalties for uncertain tax positions in income tax expense.
	The Company files federal, state and foreign tax returns. These returns are generally open to examination by the relevant tax authorities from three to four years from the date they are filed. The tax filings relating to the Company's federal and state tax returns are currently open to examination for tax years 2011 through 2013 and 2010 through 2013, respectively. In addition, the Company has generated tax losses since its inception in 2000. These years may be subject to examination if the losses are carried forward and utilized in future years.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring and Nonrecurring Basis	The following tables provides a summary of financial assets that are measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall (in thousands):
		Fair Value Measurements
		Total		Level 1		Level 2		Level 3
	31-Mar-15
	Cash Equivalents - Money Market Funds	$	123,155	$	123,155	$	—	$	—
	31-Dec-14
	Cash Equivalents - Money Market Funds	$	123,141	$	123,141	$	—	$	—
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis	The carrying amounts and the estimated fair values of financial instruments as of March 31, 2015 and December 31, 2014, are as follows (in thousands):
		31-Mar-15				December 31, 2014
		Carrying		Estimated Fair		Carrying		Estimated Fair
		Value		Value		Value		Value
	2% Convertible Senior Notes	$	170,595	$	202,377	$	168,994	$	237,475

Debt_Tables

Debt (Tables)	3 Months Ended
	Mar. 31, 2015
Outstanding Convertible Debt and Related Deferred Financing Costs	The Company had outstanding convertible debt and related deferred financing costs on its consolidated balance sheet as follows (in thousands):
		As of
		March 31,			31-Dec-14
		2015
	Principal amount of the 2% Convertible Senior Notes	$	201,250		$	201,250
	Unamortized debt discount	(30,655		)	(32,256		)
	Long-term debt, net of discount	$	170,595		$	168,994
	Deferred financing costs	$	4,693		$	4,974
Interest and Other Expense	Interest expense related to the 3.75% Notes (as defined below) and the 2% Notes was included in interest and other expense on the consolidated statements of operations as follows (in thousands):
		Three Months Ended March 31,
		2015			2014
	Contractual coupon interest	$	1,006		$	1,348
	Accretion of debt discount	1,601			2,625
	Amortization of debt issuance costs	282			146
	Total interest and other expense	$	2,889		$	4,119

Capital_Lease_Obligations_Tabl

Capital Lease Obligations (Tables)	3 Months Ended
	Mar. 31, 2015
Leases, Capital [Abstract]
Schedule of Capital Leased Assets	Assets held under capital leases consist of the following (in thousands):
		As of
		March 31, 2015			December 31, 2014
	Manufacturing equipment	$	13,705		$	7,984
	Less: Accumulated amortization	(2,400		)	(1,885		)
	Total	$	11,305		$	6,099
Schedule of Future Minimum Lease Payments for Capital Leases	The aggregate future minimum lease payments related to these capital leases as of March 31, 2015, are as follows (in thousands):
	Years Ending December 31,	Minimum Lease
		Payments
	2015 (remaining)	$	5,285
	2016	5,639
	2017	269
	Total future minimum lease payments	$	11,193
	Interest expense	(1,232		)
	Total capital lease obligations	$	9,961

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure Potential Common Shares Excluded From Computation Of Diluted Net Loss Per Share [Abstract]
Potential Common Shares Excluded from Computation of Diluted Net Loss per Share	Potential dilutive common share equivalents consist of the following:
		Three Months Ended March 31,
		2015	2014
	3.75% Convertible Senior Notes	—	5,487,642
	2.00% Convertible Senior Notes	4,327,257	—
	Unvested restricted stock units	961,947	1,024,695
	Outstanding options	2,769,259	1,722,082
	Total dilutive common shares	8,058,463	8,234,419

Accounts_Receivable_Tables

Accounts Receivable (Tables)	3 Months Ended
	Mar. 31, 2015
Receivables [Abstract]
Components of Accounts Receivable	The components of accounts receivable are as follows (in thousands):
		As of
		March 31,			31-Dec-14
		2015
	Trade receivables	$	41,469		$	45,719
	Allowance for doubtful accounts	(5,376		)	(5,837		)
	Total accounts receivable	$	36,093		$	39,882

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Components of Inventories	Inventories consist of the following (in thousands):
		As of
		March 31,		31-Dec-14
		2015
	Raw materials	$	1,616	$	853
	Work-in-process	—		254
	Finished goods	18,449		11,992
	Total inventories	$	20,065	$	13,099

Other_Intangible_Assets_Tables

Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Other Intangible Assets	Other intangible assets consist of the following (in thousands):
		As of
		March 31, 2015							31-Dec-14
		Cost		Accumulated Amortization			Net Book Value		Cost		Accumulated Amortization			Net Book Value
	Customer relationships	$	30,100	$	(19,029	)	$	11,071	$	30,100	$	(18,167	)	$	11,933
	Tradename	2,800		(716		)	2,084		2,800		(669		)	2,131
	Total intangible assets	$	32,900	$	(19,745	)	$	13,155	$	32,900	$	(18,836	)	$	14,064
Amortization Expense Expected for Next Five Years	Amortization expense expected for the next five years and thereafter is as follows (in thousands):
		Amortization Expense
	Years Ending December 31,	Customer Relationships		Tradename			Total
	2015 (remaining)	$	2,202	$	140		$	2,342
	2016	2,478		187			2,665
	2017	2,003		187			2,190
	2018	1,619		187			1,806
	2019	1,309		187			1,496
	Thereafter	1,460		1,196			2,656
	Total	$	11,071	$	2,084		$	13,155

Product_Warranty_Costs_Tables

Product Warranty Costs (Tables)	3 Months Ended
	Mar. 31, 2015
Reconciliation of Changes in Product Warranty Liability	A reconciliation of the changes in the Company’s product warranty liability is as follows (in thousands):
		Three Months Ended March 31,
		2015			2014
	Balance at the beginning of the period	$	2,614		$	3,090
	Warranty expense	467			693
	Warranty claims settled	(420		)	(683		)
	Balance at the end of the period	$	2,661		$	3,100
		As of
		March 31,			December 31,
		2015			2014
	Composition of balance:
	Short-term	$	975		$	981
	Long-term	1,686			1,633
		$	2,661		$	2,614

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Aggregate Future Minimum Lease Payments	The aggregate future minimum lease payments related to these leases as of March 31, 2015, are as follows (in thousands):
	Years Ending December 31,	Minimum Lease
		Payments
	2015 (remaining)	$	1,660
	2016	2,196
	2017	2,284
	2018	2,290
	2019	2,181
	Thereafter	6,080
	Total	$	16,691

Equity_Tables

Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stock Option Activity	The following summarizes the activity under the Company’s stock option plans:
		Number of		Weighted Average		Aggregate
		Options (#)		Exercise Price ($)		Intrinsic
						Value ($)
						(In thousands)
	Balance, December 31, 2014	1,847,669		$	26.99
	Granted	1,271,391		33.98
	Exercised(1)	(319,079	)	15.35		$	6,958
	Canceled	(30,722	)	28.11
	Balance, March 31, 2015	2,769,259		$	31.53	$	12,063
	Vested, March 31, 2015(2)	830,911		$	25.27	$	8,401
	Vested and expected to vest, March 31, 2015(2)(3)	2,538,150				$	11,696
	(1)	The aggregate intrinsic value was calculated based on the positive difference between the estimated fair value of the Company’s common stock as of the date of exercise and the exercise price of the underlying options.
	(2)	The aggregate intrinsic value was calculated based on the positive difference between the estimated fair value of the Company’s common stock as of March 31, 2015, and the exercise price of the underlying options.
	(3)	Represents the number of vested options as of March 31, 2015, plus the number of unvested options expected to vest as of March 31, 2015, based on the unvested options outstanding at March 31, 2015, adjusted for the estimated forfeiture.
Summary of Restricted Stock Units	The following table summarizes the status of the Company’s restricted stock units:
		Number of		Weighted
		Shares (#)		Average
				Fair Value ($)
	Balance, December 31, 2014	746,612		$	31.4
	Granted	418,584		33.81
	Vested	(132,476	)	29.68
	Forfeited	(70,773	)	35.72
	Balance, March 31, 2015	961,947		$	32.35

Income_Taxes_Tables

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax expense	Income tax expense consists of the following (in thousands):
		Three Months Ended March 31,
		2015		2014
	Current	$	24	$	31
	Deferred	28		34
	Total	$	52	$	65

Nature_of_Business_Details

Nature of Business (Details)	Mar. 31, 2015
	in
Nature of Business [Line Items]
Number of Inches of Tubing in conventional insulin pump	42

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
	segment	customer
	customer
	location
Significant Accounting Policies [Line Items]
Restricted Cash	$1,200,000		$1,200,000
Goodwill impairment loss	0	0
Right of return period for Starter Kits sales	45 days
Deferred revenue	$1,900,000		$1,600,000
Number of accredited financial institutions which the Company maintains the majority of its cash	2
Number of Single Source Suppliers	1	1
Number of operating segment	1
Percentage Of Accounts Payable, Accrued Expenses, and Other Current Liabilities	23.00%		24.00%
Segment Reporting, Disclosure of Major Customers	0	2
Percent of Revenue	10.00%
International Sales [Member]
Significant Accounting Policies [Line Items]
Percent of Revenue	7.00%	19.00%
One Customer [Member]
Significant Accounting Policies [Line Items]
Percent of Revenue		15.00%
Customer Two [Member]
Significant Accounting Policies [Line Items]
Percent of Revenue		13.00%

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Assets Measured on a Recurring and Nonrecurring Basis (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash Equivalents - Money Market Funds	$123,155	$123,141
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash Equivalents - Money Market Funds	123,155	123,141
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash Equivalents - Money Market Funds	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash Equivalents - Money Market Funds	$0	$0

Fair_Value_Measurements_Schedu1

Fair Value Measurements - Schedule of Liabilities Measure on Recurring and Nonrecurring Basis (Details) (2% Convertible Notes, Level 1, USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
2% Convertible Senior Notes	$202,377	$237,475
Reported Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
2% Convertible Senior Notes	$170,595	$168,994

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unamortized discount	$30,655	$32,256
2% Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal amount of Senior Notes	201,250	201,250	201,300
Unamortized discount	$30,700

Debt_Outstanding_Convertible_D

Debt - Outstanding Convertible Debt and Related Deferred Financing Costs (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Jun. 30, 2011	Jun. 30, 2014
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Unamortized discount	($30,655)	($32,256)
Long-term debt, net of discount	170,595	168,994
Deferred financing costs	4,693	4,974
3.75% Convertible Notes
Debt Instrument [Line Items]
Principal amount of Senior Notes			143,800
2% Convertible Notes
Debt Instrument [Line Items]
Principal amount of Senior Notes	201,250	201,250		201,300
Unamortized discount	-30,700
Long-term debt, net of discount	$170,600

Debt_Interest_Expense_Detail

Debt - Interest Expense (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Debt Instrument [Line Items]
Contractual coupon interest	$1,006,000	$1,348,000
Accretion of debt discount	1,601,000	2,625,000
Amortization of debt issuance costs	282,000	146,000
Loss on debt extinguishment			23,200,000
Interest and Other Expense, Total	$2,889,000	$4,119,000

Debt_Narrative_Detail

Debt - Narrative (Detail) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended	1 Months Ended
	Jul. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jun. 30, 2011	Jun. 30, 2008	Jun. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Other Assets, Fair Value Disclosure								$200,000
Loss on debt extinguishment				23,200,000
Shares Issued with debt conversion	348,535
Unamortized discount		30,655,000		32,256,000
Long-term debt, net of discount		170,595,000		168,994,000
Non-cash interest		1,883,000	2,528,000
Issuance of common stock pursuant to conversion of debt	12,600,000
5.375% Convertible Notes
Debt Instrument [Line Items]
Debt, interest rate						5.38%
Debt, maturity date						15-Jun-13
Payments of long-term debt					85,100,000
5.375% Convertible Notes | Investor
Debt Instrument [Line Items]
Unamortized discount					10,500,000
Repurchase premium					21.50%
3.75% Convertible Notes
Debt Instrument [Line Items]
Principal amount of Senior Notes					143,800,000
Amount allocated to debt	27,900,000			140,300,000			112,400,000
Amount allocated to equity	13,500,000						48,300,000
Debt Instrument, Redemption, Principal Amount	300,000
Repayment of remaining prinicpal amount including interest	300,000
Debt, interest rate					3.75%
Debt, maturity date					15-Jun-16
Debt Instrument, Repurchased Face Amount							114,900,000
Frequency of interest payment					semi-annually
Debt conversion rate					38.1749
Principal amount per note used in conversion rate					1,000
Conversion price, per share					$26.20
Deferred financing costs, amortization period					5 years
Payments of long-term debt							160,700,000
Debt Instrument repurchase premium in dollars							45,800,000
Principal Amount Of Old Debt Held							80,000,000
Interest expense related to Notes		0	1,300,000
Percentage required of the last reported sale price per share of the Company's common stock for redemption					130.00%
Number of trading days					20 days
Number of consecutive trading days					30 days
Principal amount of debt converted	28,500,000
Non-cash interest		0	2,800,000
Total Consideration Paid	41,100,000
3.75% Convertible Notes | Modified Debt
Debt Instrument [Line Items]
Unamortized discount					25,800,000
Nonconvertible debt borrowing rate					16.50%
Transaction fees					2,000,000
3.75% Convertible Notes | Debt discount related to premium payment in connection with the purchase of
Debt Instrument [Line Items]
Unamortized discount					15,100,000
3.75% Convertible Notes | Debt discount related to the increase in the value of the conversion feature.
Debt Instrument [Line Items]
Unamortized discount					200,000
3.75% Convertible Notes | New Debt
Debt Instrument [Line Items]
Unamortized discount					26,600,000
Nonconvertible debt borrowing rate					12.40%
Debt discount amortization period					5 years
Deferred financing costs					2,800,000
Finance costs reclassified against equity					900,000
Principal debt amount issued to new investors					84,300,000
3.75% Convertible Notes | Semi Annual Payment, First Payment
Debt Instrument [Line Items]
Interest payment date					December 15
3.75% Convertible Notes | Semi Annual Payment, Second Payment
Debt Instrument [Line Items]
Interest payment date					June 15
2% Convertible Notes
Debt Instrument [Line Items]
Principal amount of Senior Notes		201,250,000		201,250,000			201,300,000
Portion of 2% Notes purchased by 3.75% holders							98,200,000
Debt, interest rate		2.00%					2.00%
Debt, maturity date							15-Jun-19
Frequency of interest payment							semi-annually
Debt conversion rate							21.5019
Principal amount per note used in conversion rate							1,000
Conversion price, per share							$46.51
Unamortized discount		30,700,000
Nonconvertible debt borrowing rate							6.20%
Debt discount amortization period							5 years
Finance costs reclassified against equity							1,200,000
Deferred financing costs, amortization period							5 years
Interest expense related to Notes		1,000,000
Long-term debt, net of discount		170,600,000
Non-cash interest		1,900,000
Deferred Financing Costs, Gross							6,700,000
2% Convertible Notes | Investor
Debt Instrument [Line Items]
Unamortized discount							35,600,000
2% Convertible Notes | Semi Annual Payment, First Payment
Debt Instrument [Line Items]
Interest payment date							December 15
2% Convertible Notes | Semi Annual Payment, Second Payment
Debt Instrument [Line Items]
Interest payment date							June 15
Investor
Debt Instrument [Line Items]
Principal Amount Of Modified Debt Held					73,000,000
Investor | 5.375% Convertible Notes
Debt Instrument [Line Items]
Principal amount of Senior Notes					70,000,000
Principal Amount Of Modified Debt Held					13,500,000
Investor | 3.75% Convertible Notes
Debt Instrument [Line Items]
Principal Amount Of Modified Debt Held					$59,500,000

Capital_Lease_Obligations_Sche

Capital Lease Obligations - Schedule of Capital Leased Assets (Details) (Machinery and Equipment [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Machinery and Equipment [Member]
Capital Leased Assets [Line Items]
Manufacturing equipment	$13,705	$7,984
Less: Accumulated amortization	-2,400	-1,885
Total	$11,305	$6,099

Capital_Lease_Obligations_Sche1

Capital Lease Obligations - Schedule of Future Minimum Lease Payments for Capital Leases (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Leases, Capital [Abstract]
2015 (remaining)	$5,285
2016	5,639
2017	269
Total future minimum lease payments	11,193
Interest Expense	-1,232
Total capital lease obligations	$9,961

Capital_Lease_Obligations_Addi

Capital Lease Obligations - Additional information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Capital Leased Assets [Line Items]
Purchases of property and equipment under capital lease	$5,721,000	$0
Interest Expense	300,000	300,000
Machinery and Equipment [Member]
Capital Leased Assets [Line Items]
Manufacturing equipment	13,705,000		7,984,000
Property, Plant and Equipment, Useful Life	5 years
Amortization Expense	$500,000	$300,000
Minimum
Capital Leased Assets [Line Items]
Repayment Period for Capital Lease Obligations	24 months
Capital Leases of Lessee, Contingent Rentals, Effective Interest Rate	13.00%
Maximum
Capital Leased Assets [Line Items]
Repayment Period for Capital Lease Obligations	36 months
Capital Leases of Lessee, Contingent Rentals, Effective Interest Rate	17.00%

Net_Loss_Per_Share_Potential_C

Net Loss Per Share - Potential Common Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	8,058,463	8,234,419
3.75% Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	0	5,487,642
2% Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	4,327,257	0
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	961,947	1,024,695
Outstanding options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,769,259	1,722,082

Accounts_Receivable_Components

Accounts Receivable - Components of Accounts Receivable (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Receivables [Abstract]
Trade receivables	$41,469	$45,719
Allowance for doubtful accounts	-5,376	-5,837
Total accounts receivable	$36,093	$39,882

Accounts_Receivable_Narrative_

Accounts Receivable Narrative (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of customers that accounted for more than 10% of gross accounts receivable	1	2
Customer One
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of gross accounts receivable for major customer	13.00%	19.00%
Customer Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of gross accounts receivable for major customer		10.00%

Inventories_Components_of_Inve

Inventories - Components of Inventories (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule of Inventory [Line Items]
Raw materials	$1,616	$853
Work-in-process	0	254
Finished goods	18,449	11,992
Total inventories	$20,065	$13,099

Other_Intangible_Assets_Compon

Other Intangible Assets - Components of Other Intangible Assets (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Acquired Finite-Lived Intangible Assets [Line Items]
Other intangible assets cost	$32,900	$32,900
Less: Accumulated amortization	-19,745	-18,836
Total	13,155	14,064
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Other intangible assets cost	30,100	30,100
Less: Accumulated amortization	-19,029	-18,167
Total	11,071	11,933
Tradename [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Other intangible assets cost	2,800	2,800
Less: Accumulated amortization	-716	-669
Total	$2,084	$2,131

Other_Intangible_Assets_Amorti

Other Intangible Assets Amortization Expense Expected for Next Five Years (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Expected Amortization Expense [Line Items]
2015 (remaining)	$2,342
2016	2,665
2017	2,190
2018	1,806
2019	1,496
Thereafter	2,656
Total	13,155	14,064
Customer Relationships [Member]
Expected Amortization Expense [Line Items]
2015 (remaining)	2,202
2016	2,478
2017	2,003
2018	1,619
2019	1,309
Thereafter	1,460
Total	11,071	11,933
Tradename [Member]
Expected Amortization Expense [Line Items]
2015 (remaining)	140
2016	187
2017	187
2018	187
2019	187
Thereafter	1,196
Total	$2,084	$2,131

Other_Intangible_Assets_Narrat

Other Intangible Assets - Narrative (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2011	Dec. 31, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Other intangible assets cost			$32,900,000
Accumulated amortization	19,745,000			18,836,000
Amortization of other intangible assets	900,000	1,100,000
Intangible asset, weighted average amortization period	7 years
Intangible assets	13,155,000			14,064,000
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	19,029,000			18,167,000
Intangible assets	11,071,000			11,933,000
Tradename [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	716,000			669,000
Intangible assets	$2,084,000			$2,131,000
Maximum | Neighborhood Holdings Inc [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life	10 years
Maximum | Neighborhood Holdings Inc [Member] | Tradename [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life	15 years

Product_Warranty_Costs_Narrati

Product Warranty Costs - Narrative (Detail)	3 Months Ended
	Mar. 31, 2015
Schedule of Accrued Liabilities [Line Items]
Product warranty term for PDMs	4 years

Product_Warranty_Costs_Reconci

Product Warranty Costs - Reconciliation of Changes in Product Warranty Liability (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance at the beginning of the period	$2,614	$3,090
Warranty expense	467	693
Warranty claims settled	-420	-683
Balance at the end of the period	$2,661	$3,100

Product_Warranty_Costs_Product

Product Warranty Costs - Product Warranty Liability (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Composition of balance:
Short-term	$975	$981
Long-term	1,686	1,633
Total warranty balance	$2,661	$2,614	$3,100	$3,090

Commitments_and_Contingencies_1

Commitments and Contingencies - Operating Leases (Detail)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2013
		sqft
Billerica, Massachusetts
Operating Leased Assets [Line Items]
Area of Real Estate Property		90,000
Lease expiration date	2022-10
Singapore
Operating Leased Assets [Line Items]
Lease expiration date	2015-07
Florida
Operating Leased Assets [Line Items]
Lease expiration date	2015-12
New York
Operating Leased Assets [Line Items]
Lease expiration date	2019-01
Billerica Massachusetts, New Location - Warehouse [Member]
Operating Leased Assets [Line Items]
Lease expiration date	2019-09

Commitments_and_Contingencies_2

Commitments and Contingencies - Legal Proceedings (Details) (Office of the Massachusetts Attorney General [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Office of the Massachusetts Attorney General [Member]
Loss Contingencies [Line Items]
Litigation Settlement, Amount	$1.50

Commitments_and_Contingencies_3

Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Detail) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Minimum Lease Payments
2015 (remaining)	$1,660
2016	2,196
2017	2,284
2018	2,290
2019	2,181
Thereafter	6,080
Total	$16,691

Equity_Additional_Information_

Equity - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
	Jul. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during the period		1,271,391
Options outstanding, shares		2,769,259		1,847,669
Shares Issued with debt conversion	348,535
Stock-based compensation expense		$5,300,000	$4,400,000
Total unrecognized compensation expense		50,200,000
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		3,000,000	1,600,000
Total unrecognized compensation expense		23,600,000
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		2,300,000	2,800,000
Total unrecognized compensation expense		26,600,000
Performance based stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during the period		155,500
3.75% Convertible Notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Principal amount of debt converted	28,500,000

Equity_Stock_Option_Activity_D

Equity - Stock Option Activity (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015
Number of Options
Beginning balance (in shares)	1,847,669
Granted (in shares)	1,271,391
Exercised (in shares)	-319,079
Canceled (in shares)	-30,722
Ending balance (in shares)	2,769,259
Vested, at end of period (in shares)	830,911
Vested and expected to vest, at end of period (in shares)	2,538,150	[1]
Weighted Average Exercise Price
Beginning balance (in USD per share)	$26.99
Granted (in USD per share)	$33.98
Exercised (in USD per share)	$15.35
Canceled (in USD per share)	$28.11
Ending balance (in USD per share)	$31.53
Vested, at end of period (in USD per share)	$25.27
Aggregate Intrinsic Value
Exercised	$6,958	[2]
Ending balance	12,063
Vested, at end of period	8,401	[3]
Vested and expected to vest, at end of period	$11,696	[3]
[1]	Represents the number of vested options as of March 31, 2015, plus the number of unvested options expected to vest as of March 31, 2015, based on the unvested options outstanding at March 31, 2015, adjusted for the estimated forfeiture.
[2]	The aggregate intrinsic value was calculated based on the positive difference between the estimated fair value of the Company’s common stock as of the date of exercise and the exercise price of the underlying options.
[3]	The aggregate intrinsic value was calculated based on the positive difference between the estimated fair value of the Company’s common stock as of March 31, 2015, and the exercise price of the underlying options.

Equity_Stock_Options_Narrative

Equity - Stock Options Narrative (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding, shares	2,769,259		1,847,669
Options outstanding, weighted average exercise price	$31.53		$26.99
Options outstanding, weighted average remaining contractual life	8 years 6 months 0 days
Options exercisable, shares	830,911
Options exercisable, weighted average exercise price	$25.27
Options exercisable, weighted average remaining contractual life	6 years 7 months 17 days
Stock-based compensation expense	$5,300,000	$4,400,000
Total unrecognized compensation expense	50,200,000
Shares available for future issuance	999,090
Shares granted during the period	1,271,391
Performance based stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during the period	155,500
Employee Stock Purchase Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	0
Stock Issued During Period, Shares, Employee Stock Purchase Plans	0
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3,000,000	1,600,000
Total unrecognized compensation expense	$23,600,000
Total unrecognized compensation expense weighted-average period	1 year 6 months 0 days
Maximum | Performance based stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years

Equity_Employee_Stock_Purchase

Equity - Employee Stock Purchase Plan Narrative (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$5,300,000	$4,400,000
Employee Stock Purchase Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$0
Shares contingently issued under employee stock purchase plan	0

Equity_Restricted_Stock_Units_

Equity - Restricted Stock Units Narrative (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$5,300,000	$4,400,000
Total unrecognized compensation expense	50,200,000
Performance based stock options [Member] | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during the period	418,584
Other than options - granted in period, weighted average fair value	$33.81
Other than options - grant date fair value	14,200,000
Stock-based compensation expense	2,300,000	2,800,000
Total unrecognized compensation expense	26,600,000
Total unrecognized compensation expense weighted-average period	1 year 6 months 0 days
Restricted Stock Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during the period	0
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3,000,000	1,600,000
Total unrecognized compensation expense	$23,600,000
Total unrecognized compensation expense weighted-average period	1 year 6 months 0 days

Equity_Summary_of_Restricted_S

Equity - Summary of Restricted Stock Units (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Restricted Stock Units
Number of Shares
Beginning balance (in shares)	746,612
Granted (in shares)	418,584
Vested (in shares)	-132,476
Forfeited (in shares)	-70,773
Ending balance (in shares)	961,947
Weighted Average Fair Value
Beginning balance (in USD per share)	$31.40
Granted (in USD per share)	$33.81
Vested (in USD per share)	$29.68
Forfeited (in USD per share)	$35.72
Ending balance (in USD per share)	$32.35
Performance Shares
Number of Shares
Granted (in shares)	0
Maximum | Restricted Stock Units
Number of Shares
Vesting period	3 years

Income_Taxes_Income_Tax_Expens

Income Taxes - Income Tax Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Tax Expenses [Line Items]
Current	$24	$31
Deferred	28	34
Total	$52	$65

Income_Taxes_Narrative_Detail

Income Taxes - Narrative (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Significant Accounting Policies [Line Items]
Unrecognized Tax Benefits	0
Minimum
Significant Accounting Policies [Line Items]
Number of Open Tax Years	3 years
Maximum
Significant Accounting Policies [Line Items]
Number of Open Tax Years	4 years